Treatment indications informed by a prior implant information

• US 20090163856A1
• Filed: 12/19/2007
• Published: 06/25/2009
• Est. Priority Date: 12/19/2007
• Status: Abandoned Application

• Current Assignee: Gearbox LLC (Intellectual Ventures LLC)
• Original Assignee: Searete LLC (Intellectual Ventures LLC)
• Inventors: Ishikawa, Muriel Y., Ferren, Bran, Wood, Lowell L. JR., Rivet, Dennis J., Hyde, Roderick A., Wood, Victoria Y.H., Leuthardt, Eric C.
• Application Number:
  US12/004,453
• Publication Number:
  US 20090163856A1
• Time in Patent Office: Days
• US Class Current: 604/66
• CPC Class Codes: G16H 20/13 delivered from dispensers
• CPC Class Codes: G16H 20/40 relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture

Abstract

Systems and methods are described for implementing or deploying therapeutic administration systems for obtaining a priori implant information and signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants; or obtaining a flow-change-indicative measurement and signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement; or obtaining one or more indications of a lytic material in a vicinity of one or more body lumens and accelerating a decrease in a local concentration of the lytic material in the vicinity of the one or more body lumens by causing one or more elements to extract at least a portion of the lytic material in the vicinity of the one or more body lumens in response to the one or more indications of the lytic material in the vicinity of the one or more body lumens; or one or more capture components configured to accelerate a decrease in a local concentration of one or more therapeutic structures along a downstream portion of a vasculature and one or more dispensation components configured to release the one or more therapeutic structures into an upstream portion of the vasculature.

Claims

1. A therapeutic administration system comprising:

a processor;

one or more instructions operable by the processor to obtain a priori implant information; and

one or more instructions operable by the processor to signal a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants.

2. The therapeutic administration system of claim 1 in which the one or more instructions operable by the processor to obtain a priori implant information comprise:

one or more instructions operable by the processor to obtain the a priori implant information from one or more implantable devices.

3. The therapeutic administration system of claim 1 in which the one or more instructions operable by the processor to obtain a priori implant information comprise:

one or more instructions operable by the processor to obtain the a priori implant information from one or more objects borne by a subject.

4. The therapeutic administration system of claim 1 in which the one or more instructions operable by the processor to obtain a priori implant information comprise:

one or more instructions operable by the processor to obtain the a priori implant information ex situ.

5. The therapeutic administration system of claim 1 in which the one or more instructions operable by the processor to signal a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprise:

one or more instructions operable by the processor to obtain one or more of a blood pressure indicator or a flow rate indicator of the one or more other clot-indicative determinants.

6. The therapeutic administration system of claim 1 in which the one or more instructions operable by the processor to signal a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprise:

circuitry for generating the decision whether to initiate the implant-site-targeting treatment partly in response to an implant type.

7. The therapeutic administration system of claim 1 in which the one or more instructions operable by the processor to signal a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprise:

circuitry for deciding whether to transmit one or more other treatment indications partly based on one or more hemorrhagic-stroke-indicative determinants.

8. The therapeutic administration system of claim 1 in which the one or more instructions operable by the processor to signal a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprise:

circuitry for generating the decision whether to initiate the implant-site-targeting treatment partly in response to detecting one or more emboli.

9. The therapeutic administration system of claim 1 in which the one or more instructions operable by the processor to obtain a priori implant information comprise:

one or more instructions operable by the processor to obtain an update for the a priori implant information.

10. The therapeutic administration system of claim 1 in which the one or more instructions operable by the processor to obtain a priori implant information comprise:

one or more instructions operable by the processor to obtain timing information in the a priori implant information.

11. The therapeutic administration system of claim 1 in which the one or more instructions operable by the processor to obtain a priori implant information comprise:

one or more instructions operable by the processor to obtain an implant type of the a priori implant information.

12. The therapeutic administration system of claim 1 in which the one or more instructions operable by the processor to signal a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprise:

circuitry for generating the decision whether to initiate the implant-site-targeting treatment partly in response to an apparent change in a chemical composition.

13. The therapeutic administration system of claim 1 in which the one or more instructions operable by the processor to signal a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprise:

one or more instructions operable by the processor to signal a decision whether to dispense one or more therapeutic materials from an implant.

14. The therapeutic administration system of claim 1 in which the one or more instructions operable by the processor to signal a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprise:

one or more instructions operable by the processor to signal a decision whether to dispense one or more of a thrombolytic agent or an anticoagulant.

15. The therapeutic administration system of claim 1 in which the one or more instructions operable by the processor to signal a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprise:

circuitry for generating the decision whether to initiate the implant-site-targeting treatment partly in response to an apparent change in vascular flow.

16. The therapeutic administration system of claim 1 in which the one or more instructions operable by the processor to signal a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprise:

one or more instructions operable by the processor to obtain one or more ischemia indicators of the one or more other clot-indicative determinants.

17. The therapeutic administration system of claim 1 in which the one or more instructions operable by the processor to signal a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprise:

a flow-force-responsive element.

18. The therapeutic administration system of claim 1 in which the one or more instructions operable by the processor to signal a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprise:

an optical sensor.

19. The therapeutic administration system of claim 1 in which the one or more instructions operable by the processor to signal a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprise:

an auditory sensor.

20. The therapeutic administration system of claim 1, further comprising:

a wireless-communication device.

21. The therapeutic administration system of claim 1, further comprising:

an implant-site-targeting dispenser responsive to the decision whether to initiate the implant-site-targeting treatment.

42. The therapeutic administration system of claim 1 in which the one or more instructions operable by the processor to signal a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprise:

one or more instructions operable by the processor to signal a decision whether to dispense one or more therapeutic materials from an implant;

one or more instructions operable by the processor to signal a decision whether to dispense one or more of a thrombolytic agent or an anticoagulant;

one or more instructions operable by the processor to obtain one or more isehemia indicators of the one or more other clot-indicative determinants; and

one or more instructions operable by the processor to obtain one or more of a blood pressure indicator or a flow rate indicator of the one or more other clot- indicative determinants.

323. The therapeutic administration system of claim 1 in which the one or more instructions operable by the processor to signal a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprise:

one or more instructions operable by the processor to obtain at least a flow rate indicator of the one or more other clot-indicative determinants.

324. The therapeutic administration system of claim 1 in which the one or more instructions operable by the processor to signal a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprise:

one or more instructions operable by the processor to obtain one or more ischemia indicators of the one or more other clot-indicative determinants; and

one or more instructions operable by the processor to obtain one or more of a blood pressure indicator or a flow rate indicator of the one or more other clot-indicative determinants.

325. The therapeutic administration system of claim 1 in which the one or more instructions operable by the processor to signal a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprise:

one or more instructions operable by the processor to signal a decision whether to dispense one or more therapeutic materials from an implant;

one or more instructions operable by the processor to obtain one or more ischemia indicators of the one or more other clot-indicative determinants; and

one or more instructions operable by the processor to obtain one or more of a blood pressure indicator or a flow rate indicator of the one or more other clot-indicative determinants.

326. The therapeutic administration system of claim 1 in which the one or more instructions operable by the processor to signal a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprise:

one or more instructions operable by the processor to generate the decision whether to initiate the implant-site-targeting treatment partly in response to an implant type and partly in response to an apparent change in vascular flow.

22-41. -41. (canceled)

43. A therapeutic administration system comprising:

means for obtaining a priori implant information; and

means for signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants.

44-84. -84. (canceled)

85. A therapeutic administration method comprising:

obtaining a priori implant information; and

signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants.

116. The therapeutic administration method of claim 85 in which the obtaining a priori implant information comprises:

obtaining the a priori implant information from one or more implantable devices;

obtaining the a priori implant information ex situ;

obtaining an update for the a priori implant information;

obtaining timing information in the a priori implant information; and

obtaining an implant type.

117. The therapeutic administration method of claim 116 in which the signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprises:

generating the decision whether to initiate the implant-site-targeting treatment partly in response to one or more of an apparent change in a chemical composition, an apparent change in vascular flow, the implant type, or detecting one or more emboli;

signaling a decision whether to dispense one or more therapeutic materials from an implant;

signaling a decision whether to dispense one or more of a thrombolytic agent or an anticoagulant;

obtaining one or more ischemia indicators of the one or more other clot-indicative determinants;

obtaining one or more of a blood pressure indicator or a flow rate indicator of the one or more other clot-indicative determinants; and

deciding whether to transmit one or more other treatment indications partly based on one or more hemorrhagic-stroke-indicative determinants.

118. The therapeutic administration method of claim 85 in which the signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprises:

generating the decision whether to initiate the implant-site-targeting treatment partly in response to one or more of an apparent change in a chemical composition, an apparent change in vascular flow, an implant type, or detecting one or more emboli;

signaling a decision whether to dispense one or more therapeutic materials from an implant;

signaling a decision whether to dispense one or more of a thrombolytic agent or an anticoagulant;

obtaining one or more ischemia indicators of the one or more other clot-indicative determinants;

obtaining one or more of a blood pressure indicator or a flow rate indicator of the one or more other clot-indicative determinants; and

deciding whether to transmit one or more other treatment indications partly based on one or more hemorrhagic-stroke-indicative determinants.

86-115. -115. (canceled)

119-322. -322. (canceled)